FDA Expands Approval for Eli Lilly Therapy in Untreated Leukemia Patients
FDA approves Eli Lilly's Jaypirca for adults with untreated CLL/SLL without 17p deletion based on Phase 3 BRUIN CLL-313 trial results.
Share
Why It Matters
Eli Lilly got permission to sell a leukemia medicine to more patients. This shows the medicine works well, which is good for the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.